to improve and extend the life of cancer patients.

MCS Formulas is committed to deliver High Purity/Quality, Increased Effectiveness and Strength products as well as Individually Compiled Packages to its customers. In addition to that, one of the major commitments of MCS Formulas is to contribute to improving and extending life of cancer patients. That is why this company came to life. In order to do that we are donating 50% of our profits to academic projects addressing high-potential treatments, but do not have the financial resources to move forward.

Unfortunately, most of the academic discoveries remain confined in academic space forever due to the lack of financial resources. This often happens, because of reasons such as non-existing intellectual property that is required to convert discoveries in to profitable products. As a privately owned and ethical company, MCS Formulas has the freedom to put patients need first and allocate a major part of its profits to support high-potential academic projects.

We specifically focus on those projects that are advanced enough so that our support will help their transition to clinical space, fast. We consider treatment concepts that address oncology from various angles, with a specific focus on the metabolic approaches, addressed by both natural and synthetic compounds. Therefore, we start with a few projects that we believe can offer important value to oncology patients. Please read more about these projects below, and if you are our customer and have suggestions related to other high-potential projects, please contact us and we will strongly consider those proposals, as potential next projects.

MCS Formulas Team


The drug we have been developing as a cancer agent for the past 20 years, 2-deoxy-D-glucose, better known as 2-DG, is different than most cancer treatments in that it preferentially accumulates in cancer vs normal cells. This natural property of 2-DG provides an excellent advantage to specifically attack cancer cells while sparing normal cells. This is a fact supported by hundreds of scientific publications, including our own work along this line (1). From the beginning of our studies on 2-DG we realized that in spite of it’s potential to add value to the life of cancer patients, we would be fighting an uphill battle in developing 2-DG to be used by cancer patients. The reason for this is that 2-DG is not patentable and therefore pharmaceutical companies have little or no incentive to support research required to advance it to the clinic.



It is well accepted by now that in order to survive and develop, tumors require large amount of glucose. A good amount of this glucose is intensively processed by tumors via the fermentation process, to generate energy. During this process, as a side effect, tumors produce protons (hydrogen ions) that need to be exported outside the cell. This is because otherwise protons would acidify the cell, and reduce the internal pH to a level that would damage and possible kill the cancer cells.

Therefore, in the same way as the automobile requires an exhaust pipe to eliminate the smoke produced while the car is running, cancer cells amplify the proton transporters and proton pumps) on the cell membrane, increasing their capability to eliminate the acidity induced by protons.